AKB-9778
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for AKB-9778, covering 2015-03-27 to 2023-06-27. Get the full timeline:
Most recent: Clinical Trial Update: The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) [Phase 2]